Abstract
Lung function, symptom benefits, and safety of combined tiotropium (T) and olodaterol (O) in the treatment of COPD were established in TONADO studies (NCT01431274; NCT01431287). As T is predominantly excreted by the kidneys, we investigated the long-term safety profile of T/O in patients with renal impairment (RI) in the TONADO studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
